,i #aaith ,,congress #ast ,session ,h4 ,r4 #eaeh ,,in ,,the ,,house ,,of ,,representatives ,september #d1 #bjbe,ms4 ,scholten introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act regarding the approval of combination products consisting of a generic drug and a device1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,fair ,price ,device ,act4 #b4 ,generic drugs for use with devices ,section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;j77 is amended-- 7#a7 in paragraph 7#b77;,a7-- 7,a7 in clause 7v7-- 7i7 by striking except for changes required because of differences and inserting except for changes required or appropriate1 as determined by the ,secretary1 because of differences2 and 7ii7 by inserting 1 including changes as a result of differences that are otherwise permitted under this subsection1 such as changes as a result of appropriate differences in the device for use with the new drug before the semicolon2 7,b7 in clause 7vii71 by striking the and at the end2 7,c7 in clause 7viii7 by striking the period at the end and inserting 2 and2 7,d7 by inserting after clause 7viii7 the following new clause3 7ix7 if the listed drug referred to in clause 7i7 is intended for use with a device1 relevant information as determined by the ,secretary to support that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device when administered to patients under the conditions specified in the labeling of the drug1 which information-- 7,i7 shall be in addition to information under clauses 7i7 through 7viii7 that is relevant1 as determined by the ,secretary1 to the evaluation of the new drug for use with the device and the device proposed for use with the new drug2 and 7,,ii7 may include-- 7aa7 information 7comparative and non-comparative7 regarding the device and its performance1 including information about the compatibility of the new drug with the device and information regarding the delivery of the new drug when used with the device2 7bb7 comparative analyses of the new drug for use with the device and the listed drug for use with its device1 including information identifying any differences between the user interface of the new drug and listed drug2 information identifying any differences between the user interface of the device proposed for use with the new drug and the device used with the listed drug2 and information to show that1 despite any such differences1 the new drug when used with the device can be expected to have the same clinical effect and safety profile as the listed drug when used with the device when administered to patients under the conditions specified in the labeling of the drug2 and 7cc7 comparative and non-comparative human factors studies4 2 and 7,e7 in the matter following clause 7ix71 as inserted by subparagraph 7,d71 by striking through 7viii7 and inserting through 7ix72 and 7#b7 in paragraph 7#d7-- 7,a7 in subparagraph 7,g7-- 7i7 by striking except for changes required because of differences and inserting except for changes required or appropriate1 as determined by the ,secretary1 because of differences2 and 7ii7 by inserting 1 including changes as a result of differences that are otherwise permitted under this subsection1 such as changes as a result of appropriate differences in the device for use with the new drug before the semicolon2 7,b7 by redesignating subparagraphs 7,j7 through 7,k7 as subparagraphs 7,k7 through 7,l72 and 7,c7 by inserting after subparagraph 7,i7 the following3 7,j7 if the listed drug is intended for use with a device1 information submitted in the application is insufficient to show that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device when administered to patients under the conditions specified in the labeling of the drug2 4